These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38039515)

  • 41. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Global Longitudinal Strain in Cardio-Oncology: A Review.
    Sławiński G; Hawryszko M; Liżewska-Springer A; Nabiałek-Trojanowska I; Lewicka E
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
    Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
    Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
    Jacquinot Q; Meneveau N; Falcoz A; Bouhaddi M; Roux P; Degano B; Chatot M; Curtit E; Mansi L; Paillard MJ; Bazan F; Chaigneau L; Dobi E; Meynard G; Vernerey D; Pivot X; Mougin F
    Front Cardiovasc Med; 2022; 9():1000846. PubMed ID: 36211552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
    Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.
    Yu AF; Dang CT; Jorgensen J; Moskowitz CS; DeFusco P; Oligino E; Oeffinger KC; Liu JE; Steingart RM
    Cardiooncology; 2023 Mar; 9(1):13. PubMed ID: 36895062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heart failure from cancer therapy: can we prevent it?
    Totzeck M; Mincu RI; Heusch G; Rassaf T
    ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
    Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study.
    Moey MYY; Liles DK; Carabello BA
    Cardiooncology; 2019; 5():9. PubMed ID: 32154015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subclinical Left Ventricular Dysfunction During Chemotherapy.
    Nicol M; Baudet M; Cohen-Solal A
    Card Fail Rev; 2019 Feb; 5(1):31-36. PubMed ID: 30847243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.